PD-L1 Expression in Relation to Patients With Thyroid Cancer
Christine Dierks, MD, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.
Christine Dierks, MD, senior physician at the University Hospital Freilburg in Germany, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.
Dierks says that regarding the PD-L1 levels used for the tumor proportion score (TPS) and combined positive score (CPS), physicians look at the PD-L1 expression on the membrane of the tumor cells. They also look at the frequency of the infiltrating immune cells and infiltrating lymphocytes to see if they express PD-L1 or PD-1 on the cell’s surface. To histologically characterize the immune phenotype of a tumor, they need to see the level of expression on these different parts of the tumor.
With differentiated thyroid carcinoma, physicians usually see TPS that is either negative or very low, below 10%. In over 70% of patients with anaplastic thyroid carcinoma, the TPS is often above 50% and the CPS above 75%, according to Dierks. She says these scores are some of the prognostic markers for response to immune checkpoint inhibitors in patients with non–small cell lung cancer.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
